Cover Image

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review

Marcello Tiseo, Andrea Ardizzoni
  • Marcello Tiseo
    Division of Medical Oncology, University Hospital of Parma, Parma; Division of Medical Oncology, University Hospital of Parma, Italy | mtiseo@ao.pr.it
  • Andrea Ardizzoni
    Division of Medical Oncology, University Hospital of Parma, Italy

Abstract

Cisplatin has a pivotal role in the treatment of non-small cell lung cancer (NSCLC). However, it is associated with a number of serious and unpleasant side effects (nausea-vomiting, myelo-suppression, neuro-toxicity and renal function impairment). To overcome these limitations, most clinicians have turned towards the use of the cisplatin analog carboplatin, which is associated with a lower incidence of toxicity. Although carboplatin and cisplatin have a similar mechanism of action and pre-clinical spectrum of activity, it is still unclear whether they actually have the same clinical efficacy in all types of tumors. While for some tumors, such as ovarian cancer, equivalent efficacy has been convincingly proven, for others, such as germ cell and headneck tumors, there is some evidence that carboplatin is inferior to cisplatin. It has never been convincingly proven that carboplatin and cisplatin have the same efficacy in the treatment of NSCLC. This review provides an update of available evidences about this important scientific question.

Keywords

Non-small cell lung cancer - Cisplatin - Carboplatin

Full Text:

FULL TEXT
Submitted: 2011-12-18 12:45:12
Published: 2011-12-18 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
779

Views:
FULL TEXT
204

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2011 Marcello Tiseo, Andrea Ardizzoni

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185